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Abstract 
 
We conducted a meta-analysis of three endometrial cancer (EC) GWAS and two replication 
phases totaling 7,737 EC cases and 37,144 controls of European ancestry. Genome-wide 
imputation and meta-analysis identified five novel risk loci at genome-wide significance at 
likely regulatory regions on chromosomes 13q22.1 (rs11841589, near KLF5), 6q22.31 
(rs13328298, in LOC643623 and near HEY2 and NCOA7), 8q24.21 (rs4733613, telomeric to 
MYC), 15q15.1 (rs937213, in EIF2AK4, near BMF) and 14q32.33 (rs2498796, in AKT1 near 
SIVA1). A second independent 8q24.21 signal (rs17232730) was found. Functional studies 
of the intergenic 13q22.1 locus showed that rs9600103 (pairwise r2=0.98 with rs11841589) 
is located in a region of active chromatin that interacts with the KLF5 promoter region. The 
rs9600103-T EC protective allele suppressed gene expression in vitro suggesting that the 
regulation of KLF5 expression, a gene linked to uterine development, is implicated in 
tumorigenesis. These findings provide enhanced insight into the genetic and biological basis 
of EC. 
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Endometrial cancer (EC) is the fourth most common cancer in women in the United States1 
and Europe2, and the most common cancer of the female reproductive system. The familial 
relative risk is ~23,4, but highly penetrant germline mutations in mismatch repair genes5, and 
DNA polymerases6,7 account for only a small proportion of the familial aggregation. Our 
previous GWAS and subsequent fine-mapping identified the only two reported genome-wide 
significant EC risk loci, tagged by rs11263763 in HNF1B intron 18 and rs727479 in CYP19A1 
intron 49.  
 
To identify additional EC risk loci, we re-analysed data from our previous GWAS (ANECS, 
SEARCH datasets10) and conducted a meta-analysis with two further studies 
(Supplementary Figure 1). The first was an independent GWAS; the National Study of 
Endometrial Cancer (NSECG), including 925 EC cases genotyped using the Illumina 660W 
array, 1,286 cancer-free controls from the CORGI/SP1 GWAS11,12 and 2,674 controls from 
the 1958 Birth Cohort13. The second study comprised 4,330 EC cases and 26,849 controls 
from Europe, the United States and Australia, genotyped using a custom array designed by 
the Collaborative Oncological Gene-environment Study (COGS) initiative14–17 
(Supplementary Table 1, Supplementary Note).  
 
We first performed genome-wide imputation using 1000 Genomes Project data, allowing us 
to assess up to 8.6 million variants with allele frequency 1% across the different studies. 
Per-allele odds ratios and P-values for all SNPs in the GWAS and iCOGS were obtained 
using a logistic regression model. There was little evidence of systematic overdispersion of 
the test statistic (λGC=1.002-1.038, Supplementary Figure 3). A fixed-effects meta-analysis 
was conducted for all 2.3 million typed and well-imputed SNPs (info score>0.90) in a total of 
6,542 EC cases and 36,393 controls.  The strongest associations were with SNPs in LD with 
previously identified EC risk SNPs in HNF1B10,8,18 and CYP19A19,19 (Figure 1, Table 1). For 
fourteen 1.5Mb regions containing at least one novel SNP with Pmeta<10
−5, we performed 
regional imputation using an additional reference panel that comprised 196 high-coverage 
whole genome-sequenced UK individuals (Supplementary Table 2).  
 
Five novel regions containing at least one EC risk SNP with Pmeta<10
−7 were identified and 
the most strongly associated SNP in each region was genotyped in an additional 1,195 
NSECG EC cases and 751 controls using competitive allele-specific PCR (KASPar, 
KBiosciences) and the Fluidigm BioMark System (Supplementary Table 3). Duplicate 
samples displayed concordance >98.5% between different genotyping platforms 
(Supplementary Table 4). All five SNPs were associated with EC at genome-wide 
significance (P<5×10−8, Table 1, Figure 2), and these associations remained highly 
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significant when analysis was restricted to cases with endometrioid subtype only. 
Endometrioid-only analysis did not reveal any additional risk loci.  eQTL analysis (Online 
Methods)  in normal uterine tissue,20 and EC tumour and adjacent normal tissue21 did not 
yield any SNPs robustly associated with the expression of nearby genes at the EC risk loci 
(Supplementary Table 7). However, for each risk locus, bioinformatic analysis including 
cell-type-specific expression and histone modification data identified correlated SNPs within 
500kb in likely enhancers and multiple potential regulatory targets (Supplementary Table 6, 
Supplementary Figure 5). The most compelling candidates for future functional analysis 
are described below. 
 
rs13328298 (OR=1.13, 95%CI:1.09–1.18, P=3.73×10−10) on 6q22.31 lies in the long non-
coding RNA LOC643623, 54kb upstream of HEY2 and 86kb upstream of NCOA7. HEY2 is a 
helix-loop-helix transcriptional repressor in the Notch pathway, which maintains stem cells, 
and dysregulation has been associated with different cancers22. NCOA7 modulates the 
activity of the estrogen receptor via direct binding23.  
 
The second locus (rs4733613, OR=0.84, 95%CI:0.80–0.89, P=3.09×10−9) is at 8q24.21. 
Stepwise conditional logistic regression identified another independent signal in this region, 
rs17232730 (pairwise r2=0.02, Pcond=1.29×10
−5, Table 2). Both EC SNPs lie further from 
MYC (784-846kb telomeric) than most of the other cancer SNPs in the region, including 
those for cancers of the bladder24,25, breast26,16, colorectum11,27, ovary28 and prostate29,30. 
rs17232730 is in moderate LD with the ovarian cancer SNP rs10088218 (r2=0.43), with both 
cancers sharing the same risk allele, but rs4733613 is not in LD (r2≤0.02) with any other 
cancer SNP in the region (Supplementary Figure 5). A role in tumorigenesis is implicated 
for several miRNAs in the region31. Of these, miR-1207-5p is reported to repress TERT, a 
locus also implicated in EC risk32. 
 
The lead SNP at 15q15 (rs937213; OR=0.90, 95%CI:0.86–0.93, P=1.77×10−8) lies within an 
intron of EIF2AK4. EIF2AK4 encodes a kinase that phosphorylates EIF2α and 
downregulates protein synthesis during cellular stress33. Another nearby gene, BMF, 
encodes an apoptotic regulator moderately to highly expressed in glandular endometrial 
tissue34.  
 
At 14q42, the lead SNP rs2498796 (OR=0.89, 95%CI:0.85–0.93, P=3.55×10−8) lies in intron 
3 of oncogene AKT1, which is highly expressed in the endometrium34. Several SNPs in LD 
with rs2498796 are bioinformatically linked with regulation of AKT1 and four other nearby 
genes (SIVA1, ZBTB42, ADSSL1 and INF2; Supplementary Table 6, Supplementary 
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Figure 5). AKT1 acts in the PI3K/AKT/MTOR intracellular signaling pathway, which affects 
cell survival and proliferation35 and is activated in endometrial tumors36, especially 
aggressive disease37,38,39. SIVA1 encodes an apoptosis regulatory protein that inhibits p53 
activity40,41 and enhances epithelial–mesenchymal transition to promote motility and 
invasiveness of epithelial cells42. INF2 expression is reported to act as a promigratory signal 
in gastric cancer cells treated with mycophenolic acid43.  
 
The final novel EC SNP was rs11841589 (OR=1.15, 95%CI:1.11–1.21, P=4.83×10−11) on 
chromosome 13q22.1, 163kb and 445kb downstream from Kruppel-like factors KLF5 and 
KLF12, respectively. KLF5 is a transcription factor associated with cell cycle regulation, and 
it plays a role in uterine development, homoeostasis and tumorigenesis44–47. Elevated KLF5 
levels are strongly correlated with activating KRAS mutations48 and KLF5 is targeted for 
degradation by the tumor suppressor FBXW7. Both FBXW7 and KRAS are commonly 
mutated in EC49. rs11841589 was one of a group of five highly correlated SNPs (r20.98) 
surpassing genome wide significance in a 3kb LD block bounded by rs9600103 
(P=8.70×10−11) and rs11841589 (Figure 4a). There was no residual association signal at 
this locus (Pcond >0.05) after conditioning for rs11841589.  Bioinformatic analysis suggested 
that the causal variant at the intergenic 13q22.1 locus may affect a regulatory element that 
modifies KLF5 expression (Supplementary Figure 5); rs9600103 overlaps a vertebrate 
conservation peak, and a DNaseI hypersensitivity site (DHS) in estrogen and tamoxifen-
treated ENCODE50 Ishikawa cells (Figure 4a). In addition, in a Hi-C chromatin capture 
experiment in Hela S3 cells51, an interaction loop was observed between a segment 
containing the KLF5 promoter and the rs11841589/rs9600103 locus (P=0.004, 
Supplementary Figure 6).  
 
We further investigated the epigenetic landscape of a 16kb region around rs11841589 and 
rs9600103 that contained the SNPs most strongly associated with EC, by analysis of three 
EC cell lines: Ishikawa is homozygous for the rs9600103-A and rs11841589-G high-risk 
alleles, and provided a comparison with the ENCODE data; ARK-2 is homozygous for the 
low-risk T alleles at both SNPs; and AN3CA is a non-KLF5 expressing line that is 
homozygous for the high-risk alleles (Supplementary Figure 7). We conducted 
formaldehyde-assisted identification of regulatory elements (FAIRE, to identify regions of 
open chromatin), and chromatin immunoprecipitation (ChIP) using antibodies against 
H3K4Me2 (marker of transcription factor binding52) and panH4Ac (marker of active 
chromatin). Although the anti-H4Ac ChIP did not display a consistent signal in the region, 
signals from FAIRE and anti-H3K4Me2 ChIP were specifically present in the KLF5-
expressing lines and were co-located with the conservation peak and DHS from the 
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ENCODE data at rs9600103, providing strong evidence for open chromatin and transcription 
factor binding here (Figure 4a).  We then conducted chromatin conformation capture 
experiments for the KLF5-expressing Ishikawa endometrial cancer cells and we found a 
significant interaction between the NcoI restriction fragment containing the 
rs11841589/rs9600103 risk loci SNPs and the promoter region of KLF5 (Figure 4b).  
 
The regulatory nature of the region around rs9600103 and rs11841589 was investigated 
using allele-specific luciferase enhancer reporter assays in Ishikawa cells (Figure 4c). 
Paired t-tests were used to compare the relationships between fragments containing the 
rs11841589 and rs9600103 alleles, and the pGL3-Promoter reporter vector (no insert) 
control (Supplementary Table 8). Fragments containing the rs9600103-T, rs11841589-T 
and rs11841589-G alleles had activity significantly lower than that of the pGL3-Promoter 
control (P≤0.014). In contrast, the construct containing the rs9600103-A risk allele had 
luciferase expression similar to the pGL3-Promoter control (P=0.23) and significantly higher 
than that of rs9600103-T (P=0.02), rs11841589-T (P=0.05) and rs11841589-G (P=0.04). 
These results suggest that the EC risk tagged by rs11841589 is at least partly due to a 
regulatory element containing rs9600103, which interacts with the KLF5 promoter region, 
and the risk rs9600103-A allele is likely associated with increased gene expression.  
In summary, this meta-analysis identified five novel EC risk loci at genome-wide 
significance, bringing the total number of common EC risk loci identified by GWAS to seven 
(Figure 1). Together with other risk SNPs reaching study-wide significance32,53,54, these 
explain ~1.6% of the EC familial relative risk. Novel EC risk SNPs lie in likely enhancers 
predicted to regulate genes or miRNAs with known or suspected roles in tumorigenesis, and 
we specifically showed that a functional SNP at 13q22.1 may sit within a transcriptional 
repressor of KLF5. Our findings further clarify the genetic etiology of EC, provide regions for 
functional follow-up, and add key information for future risk stratification models. 
 
 
 
Methods 
 
Methods and any associated references are available in the online version of the paper at 
http://www.nature.com/naturegenetics/. 
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Table 1: Risk loci associated with EC at P< 5×10−8 in the meta-analysis.  
 
Locus SNP Position 
Nearby 
gene(s) 
EA OA EAF 
All histologies Endometrioid histology 
Allelic OR 
(95%CI) 
P I
2
 
Allelic OR 
(95%CI) 
P I
2
 
Novel GWAS loci             
13q22.1 rs11841589 73,814,891 KLF5, KLF12 G T 0.74 1.15 (1.11-1.21) 4.83×10
−11
 0.19 1.16 (1.10-1.21) 6.01×10
−10
 0.00 
6q22.31 rs13328298 126,016,580 
HEY2, 
NCOA7 
G A 0.58 1.13 (1.09-1.18) 3.73×10
−10
 0.00 1.15 (1.11-1.20) 1.02×10
−11
 0.00 
8q24.21 rs4733613 129,599,278 MYC G C 0.87 0.84 (0.80-0.89) 3.09×10
−9
 0.00 0.84 (0.79-0.89) 7.70×10
−9
 0.09 
15q15.1 rs937213 40,322,124 
EIF2AK, 
BMF 
T C 0.58 0.90 (0.86-0.93) 1.77×10
−8
 0.36 0.90 (0.86-0.94) 2.22×10
−7
 0.30 
14q32.33 rs2498796 105,243,220 AKT1, SIVA1 G A 0.70 0.89 (0.85-0.93) 3.55×10
−8
 0.00 0.88 (0.85-0.92) 4.22×10
−8
 0.00 
Previously reported GWAS loci            
17q12 rs11263763 36,103,565 HNF1B A G 0.54 1.20 (1.15-1.25) 2.78×10
−19
 0.37 1.20 (1.15-1.25) 6.51×10
−17
 0.52 
15q21 rs2414098 51,537,806 CYP19A1 C T 0.62 1.17 (1.13-1.23) 4.51×10
−13
 0.00 1.18 (1.13-1.23) 2.48×10
−13
 0.00 
 
Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency; I2, heterogeneity I2 statistic55.  For all novel loci, the lead 
SNP was either directly genotyped or imputed with an information score of more than 0.9. HNF1B and CYP19A1 have been previously reported 
by Painter et al.8 and Thompson et al9.  
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Table 2: Conditional analysis of 8q24 locus showing two independent association signals. 
 
SNP Position EA OA EAF 
Pairwise r
2 
with All histology meta-analysis Conditioning on rs4733613 Conditioning on rs17232730 
rs4733613 rs17232730 Allelic OR (95%CI) P Allelic OR (95%CI) P Allelic OR (95%CI) P 
rs4733613 129,599,278 G C 0.87 - 0.02 0.84 (0.79-0.89) 5.64 × 10
−9
 - - 0.86 (0.81-0.91) 2.32 × 10
−7
 
rs17232730 129,537,746 G C 0.88 0.02 - 1.17 (1.10-1.24) 4.46 × 10
−7
 1.14 (1.08-1.22) 1.29 × 10
−5
 - - 
rs10088218* 129,543,949 G A 0.87 0.02 0.43 1.14 (1.07-1.20) 1.65 × 10
−5
 1.12 (1.05-1.18) 2.92 × 10
−4
 1.01 (0.91-1.12) 0.818 
 
 
Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency. 
*rs10088218 is associated with ovarian cancer (all subtypes), with the association being more significant for cancers of serous histology. 
rs10088218-G is the risk allele for both EC and ovarian cancer. 
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Figure legends 
 
Figure 1: EC meta-analysis Manhattan plot 
Manhattan plot of –log10-transformed P-values from meta-analysis of 22 autosomes. There 
are seven loci surpassing genome wide significance including two known loci: 15q21 
(CYP19A1) and 17q12 (HNF1B) and five novel loci: 6q22 (NCOA7, HEY2), 8q24 (MYC), 
13q22 (KLF5), 14q32 (AKT1, SIVA1), 15q15 (EIF2AK4, BMF).  
 
Figure 2: Forest plots of novel EC risk loci 
The odds ratio and 95% confidence intervals of each study of the meta-analysis are listed 
and shown in the adjacent plot. The I2 heterogeneity scores (all <0.4) suggest that there is 
no marked difference in effects between studies. The SNPs represented are: a) rs11841589 
(13q22), b) rs13328298 (6q22), c) rs4733613 (8q24), d) rs17232730 (8q24, pairwise r2 0.02 
with rs4733613), e) rs937213 (15q15) and f) rs2498796 (14q32).  
 
Figure 3: Regional association plots for the five novel loci associated with EC.  
The -log10 P-values from the meta-analysis and regional imputation for three GWAS and 
eight iCOGS groups are shown for SNPs at: a) 13q22.1, b) 6q22, c) & d) 8q24, e) 15q15 and 
f) 14q32.33. The SNP with the lowest P-value at each locus is labeled and marked as a 
purple diamond, and the dot color represents the LD with the top SNP. The blue line shows 
recombination rates in cM/Mb. All plotted SNPs are either genotyped or have an IMPUTE 
info score of more than 0.9 in all datasets. Supplementary Figure 4 displays similar 
regional association plots with a larger number of SNPs using a less stringent info score cut-
off.  
 
Figure 4: The 13q22.1 EC susceptibility locus 
a) Diagram showing the 16kb region (position 73,804,930- 73,820,618) around rs11841589, 
rs9600103 and correlated SNPs rs7981863, rs7988505 and rs7989799 (black marks). 
FAIRE and ChIP assays with anti-H3K4Me2 and anti-H4Ac antibodies for three EC cell lines 
ARK-2 (rs9600103-TT), Ishikawa (rs9600103-AA) and AN3CA (rs9600103-AA) are shown, 
with the y-axis displaying enrichment normalized to non-crosslinked genomic DNA/sonicated 
input DNA, relative to the Rhodopsin promoter as a negative control using the ΔΔCt method. 
DNaseI hypersensitivity site (DHS) density signal in ENCODE EC Ishikawa cells 
(Supplementary Note) are shown, from experiments with cell lines treated with estrogen 
and tamoxifen. 100 vertebrates conservation is also displayed. Vertical dotted line 
represents the position of rs9600103.  
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b) 3C experiment for KLF5-expressing Ishikawa cells. Relative interaction frequencies 
between an NcoI restriction fragment containing risk SNPs rs9600103 and rs11841589 (bait 
fragment) with NcoI fragments across the region were calculated using qPCR with 
normalization to the signal from a control BAC 3C library and a non-interacting chromosomal 
region, using the ΔΔCt method. The graph shows the frequencies plotted against the 
fragment position on chromosome 13. A significant interaction is seen with the fragment 
containing a KLF5 transcriptional start site in Ishikawa cells. 
c) Luciferase reporter assay to analyze the activity of 3kb fragments containing either 
rs9600103 or rs11841589 using the pGL3 promoter vector in Ishikawa cells. Green arrows 
represent the low-risk alleles, and red arrows the high-risk alleles. Error bars represent the 
standard error of the mean. Data were normalized by subtraction of background 
luminescence and normalized to pGL4 Renilla activity. Luciferase activity in the rs9600103-A 
risk allele was more than double than that of the rs9600103-T protective allele (P=0.018). 
Paired t-tests between the different fragments also showed that the rs9600103-A high-risk 
allele has significantly higher expression compared with both rs11841589 alleles (0.045, 
0.039) (Supplementary Table 8).  Schematic diagram displays position on chromosome 13 
of the fragment sequences and the arrows represents the position of the two SNPs. 
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ONLINE METHODS 
 
Cases and controls were matched as summarized in Supplementary Table 1 and a 
detailed description of each sample set can be found in the Supplementary Note. 
Supplementary Figure 1 is a flow diagram that illustrates the overall study design.  
 
 
Additional EC GWAS 
 
The National Study of Endometrial Cancer Genetics (NSECG) consisted of 925 histologically 
confirmed endometrial cancer (EC) cases from the UK. 86% of these cases had 
endometrioid-only histology and genotyping was done using Illumina 660W Quad arrays.  
 
These cases were matched with 1,286 cancer-free controls from the UK1/CORGI1 and SP12 
colorectal studies with genotyping conducted on Illumina Hap550, Illumina Hap300 and 
Illumina Hap240S arrays. Additionally, publically available 1958 Birth Cohort3 controls from 
the Wellcome Trust Case Control Consortium (WTCCC2)4 genotyped on Illumina Infinium 
1.2M arrays were included.  
 
 
Original EC GWAS 
 
As described previously, cases with confirmed endometrioid histology were selected from 
two population studies of endometrial cancer; the UK Studies of Epidemiology and Risk 
factors in Cancer Heredity (SEARCH, n=681) and the Australian National Endometrial 
Cancer Study (ANECS, n=606), and genotypes generated using Illumina Infinium 610K 
arrays5. Compared with our previous study5, ANECS and SEARCH were analysed as two 
groups and additional controls6,7were used for this meta-analysis.  SEARCH cases were 
compared with 2,501 controls from the National Blood Service (NBS) part of the WTCCC2 
controls4. ANECS cases were compared to controls recruited as part of the Hunter 
Community Study6 or Brisbane Adolescent Twin Study8, both genotyped using the Illumina 
Infinium 610K arrays.  
 
 
Phase 1 iCOGS replication 
 
For the iCOGS genotyping stage of the study, 4,330 women with a confirmed diagnosis of 
endometrial cancer and European ancestry were recruited via 11 separate studies in 
Western Europe, North America and Australia, collectively called the Endometrial Cancer 
Association Consortium (ECAC).  
 
Healthy female controls with European ancestry and known age at sampling were selected 
from controls genotyped by the Breast Cancer Association Consortium (BCAC)9 iCOGS 
project, or the Ovarian Cancer Association Consortium (OCAC)10 iCOGS project. The eight 
case-control groups were matched based on geographical location, and principal 
components analysis (PCA) was conducted such that individuals who clustered outside the 
main centroid in pairwise plots of the first four PCs were excluded (Supplementary Figure 
2). 
 
Cases and controls were genotyped on a custom Illuminia Infinium iSelect array with 
211,155 SNPs, designed by the Collaborative Oncological Gene-environment Study 
(iCOGS), a collaborative project involving four consortia. SNPs were included on this array 
based on promising regions of interest in previous breast, ovarian and prostate11 studies, 
and also the 1,483 top SNPs from our previous EC GWAS5 analysis. Cases and MoMaTEC 
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controls were genotyped by Genome Quebec Innovation Center. BCAC and OCAC control 
samples were genotyped at four centres.  Raw intensity data files for all consortia were sent 
to the COGS data co-ordination centre at the University of Cambridge for centralized 
genotype calling and QC, so that all case and control genotypes were called using the same 
procedure. 
 
 
SNP genotyping arrays quality control 
 
Genotype calling was done using Illumina’s proprietary Gencall algorithm and Illumnus12. 
Duplicate samples displayed >99% concordance. Standard quality control measures applied 
to genotyping arrays are described in our original GWAS5 and these include genotypic call 
rate <0.95, deviation from Hardy-Weinberg Equilibrium (HWE) at P<10-6 and visual 
inspection of cluster plots for most significant SNPs. For iCOGS, all EC cases and 
MoMaTEC controls were genotyped by Genome Quebec Innovation Center. BCAC and 
OCAC control samples were genotyped at four centres.  Raw intensity data files for all 
consortia were sent to the COGS data co-ordination centre at the University of Cambridge 
for centralized genotype calling and QC, so that all case and control genotypes were called 
using the same procedure. Duplicate samples for quality showed a concordance of >99%. 
Samples were excluded based on the following measures: missingness >5%, heterozygosity 
rates ((N-O)/N) > 5 S.D from the mean, X chromosome heterozygosity rate (PLINK F-score) 
>0.2, and pairwise identity by descent (IBD) >0.1875 (cut-off for second-degree relatives). 
Principal components analysis (PCA) was conducted using Eigenstrat13 software. Analysis 
was conducted using PLINK14, and R packages GenABEL and SNPMatrix15,16.  
 
 
Phase 2 NSECG replication 
 
The second replication phase consisted of directly genotyping five SNPs with P<10-7 and 
IMPUTE info scores of >0.94 from the NSECG/ANECS/SEARCH/iCOGS meta-analysis. 
Genotyping was done in NSECG samples that had not previously been used in the NSECG 
GWAS or the NSECG iCOGS. Genotyping was conducted using competitive allele-specific 
PCR (KASPar, KBiosciences) and the Fluidigm BioMarkTM HD System, using standard 
protocols. The genotyping call rate was >0.98 and there was a >0.985 concordance between 
different genotyping platforms (Supplementary Table 4). There was no significant deviation 
from HWE (P>0.05). Primers used for genotyping are listed in Supplementary Table 5.  
 
 
Genome-wide and regional imputation 
 
Genome-wide imputation for all SNP array generated data was conducted using IMPUTE 
v217 using 1000 Genomes project (2012 release) as a reference panel. For the first-pass 
genome-wide analysis we pre-phased chromosomes using SHAPEIT18 to improve the 
computational speed.  Imputation was carried out separately for the each of the three GWAS 
studies (for each GWAS study the cases and controls were imputed together as a single 
dataset, using only SNPs which passed QC in both cases and controls) and for the iCOGS 
study (all studies within iCOGS were imputed together).  SNPs with MAF<0.1% were 
removed from all studies prior to imputation. Genome-wide imputation produced 9,594,066 
SNPs with MAF≥1% and info≥0.4 in at least one of the three GWAS and eight iCOGS 
groups. Of these, 8,308,423 SNPs met these criteria in all studies. The iCOGS genotyping 
array (~200,000 SNPs) is aimed at capturing previously prioritised cancer SNPs and not 
genome-wide coverage, but nonetheless 8,631,871 SNPs met MAF≥1% and info≥0.4 
criteria, of which 5,437,135 had info≥0.7 and 2,333,040 had info≥0.9. 
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Regional imputation of regions of interest (1.5Mb region around SNPs with meta-analysis 
P<10-5) used both 1000 Genomes 2012 release and 196 high-coverage, whole genome-
sequenced UK individuals as reference panels as a means to improve imputation 
accuracy19. All SNPs reported in this study had an info score of more than 0.9 in all datasets.  
 
 
 
Association testing 
 
Association testing was done using SNPTEST v220 employing frequentist tests with a logistic 
regression model for each of the 11 groups as matched in Supplementary Table 1. There 
was little evidence of systematic over-dispersion of the test statistic from the quantile-
quantile plots (Supplementary Figure 3) and the genomic inflation λGC, calculated using all 
genotyped SNPs passing QC for the three GWAS. For iCOGS, 105,000 SNPs after LD-
pruning (r2<0.2) and >500kb from the 1,483 EC prioritized SNPs on the iCOGS were used. 
λGC was between 1.002 and 1.038 for each study. Conditional logistic regression analysis 
was conducted for each locus of genome-wide significance using SNPTEST to look for the 
presence of multiple independent association signals. This was done in a stepwise manner, 
first conditioning for the most significant SNP and subsequently for any SNPs that remained 
significant at Pcond<10
-4. Regional association plots (Figure 1, Supplementary Figure 4) 
were created using LocusZoom21.  
 
 
Meta-analysis 
 
Inverse variance, fixed effects meta-analysis of the 11 groups (three GWAS, eight iCOGS 
groups) was conducted using GWAMA22. The per allele effect size of each SNP in a 
particular study is represented by  (the log-odds ratio) and its standard error.  Inter-study 
differences are represented by the I2 heterogeneity score23,24. Forest plots of the genome-
wide significant loci (Figure 2) provided a visual representation of risk effects across 
different studies and these were made using the rmeta package (http://cran.r-
project.org/web/packages/rmeta/).  A random-effects meta-analysis was also performed for 
SNPs with I2>0.3.  The results of the second replication phase (NSECG replication) were 
meta-analyzed in a 12-way meta-analysis for the top 5 SNPs yielding a total of 7,737 EC 
cases and 37,144 controls. 6,635 (86%) of the EC cases had endometrioid-only histology 
and association testing and meta-analysis were also conducted with just these samples.  
 
 
Bioinformatic analysis and functional annotation of genome-wide significant EC risk 
loci 
 
The five novel genome-wide significant loci and SNPs in LD (r2>0.7 in European 1000 
Genomes) were annotated using HaploregV225, RegulomeDB26 and data from ENCODE27 in 
Supplementary Table 6. This includes information such as promoter and enhancer histone 
marks, DHS, bound proteins, altered motifs, GENCODE and dbSNP annotations, 
RegulomeDB score and PhastCons conservation scores.  
 
Bioinformatic analysis in Supplementary Figure 6 used datasets described by Hnisz et al.28 
and Corradin et al.29 in order to identify likely enhancers in a cell-specific context for the EC 
risk loci. Enhancer-gene interactions are predicted by identifying 'super-enhancers' (regions 
containing neighbouring H3K27Ac modifications) from 86 cell and tissue types and then the 
expressed transcript with transcription start site closest to the centre of the super-enhancer 
was assigned as the target gene. PresTIGE pairs cell-type specific H3K4Me1 and gene 
expression data from 13 cell types to identify likely enhancer-gene interactions. 
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Endometrial-tissue expression quantitative trait loci (eQTL) analysis for associated 
SNPs using GTEx and TCGA data 
 
Publicly available data generated by the Genotype-Tissue Expression Project (GTEx)30 and 
The Cancer Genome Atlas (TCGA; www.cancergenome.nih.gov) were accessed to examine 
tissue-specific eQTLs. For GTEx, expression and genotype data were generated from 70 
normal uteri from post-mortem biopsies, using an Affymetrix Expression array and Illumina 
Omni 5M SNP array. GTEx provided processed results, evaluating association between 
genotype and expression data. The expression levels are represented as a rank normalized 
score. TCGA genotype and copy number variation (CNV) data were derived from Affymetrix 
6.0 SNP arrays. Expression data were from RNAseq arrays (Illumina HiSeq and Illumina 
GA) for 458 endometrial cancer tissues and 30 adjacent normal endometrial tissues. 
Association analyses for TCGA datasets were performed as follows. Genes within 500kb 
flanking our SNPs of interest were selected for analysis. Since there may be significant 
variation in tumour tissue copy number, somatic CNVs were taken into account by 
regressing gene expression to average copy number spanning the gene. Residual 
unexplained variance in gene expression was then regressed on the genotype of the lead 
SNP at each locus, using genotyped or imputed data. Statistical comparisons were subject 
to Bonferroni correction for number of tests (number of sample sets, and number of genes 
assessed). 
 
 
DNA and RNA extraction from EC cell lines 
 
Cells were snap frozen with dry ice after centrifugation, and DNA and RNA were extracted 
using DNeasy DNA extraction (Qiagen) and RNeasy minikit (Qiagen) according to 
manufacturer's instructions. Nucleic acids were then quantified using Nanodrop 2000 
(ThermoScientific) spectrophotometry. 
 
 
Quantification of KLF5 expression in 11 EC cell lines 
 
Extracted RNA was treated with DNase 1 and complimentary DNA (cDNA) was reverse 
transcribed from RNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems), according to the manufacturer's protocol. TaqMan Gene Expression Assays 
were used for KLF5 and GAPDH (details available from authors). The absolute expression 
of KLF5 was quantified using qRT-PCR using the ABI 7900HT cycler (Applied Biosystems), 
and the critical threshold was manually set at 0.2. Standard protocols were applied to 
calculate relative expression using the ΔΔCT method as described by Livak and 
Schmittgen31 and GAPDH was used as an endogenous control.  
 
 
Formaldehyde-assisted identification of regulatory elements (FAIRE)  
 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) was conducted using the 
method adapted from Giresi et al32. Briefly, cross-linking was done on a rocker at room 
temperature. 1% formaldehyde was added to approximately 108 cells for 5 minutes, after 
which 115 mM glycine was added to inhibit the cross-linking. For each cell line, a non-
crosslinked control was prepared in parallel for all of the remaining steps. After two rinses 
with 4C phosphate buffered saline solution (PBS), the cells were suspended in successive 
lysis buffers: Lysis buffer I (50 mM HEPES-KOH, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 
0.5% NP-40, 0.25% tritonX-100); lysis buffer II (10 mM tris-HCl, 200 mM NaCl, 1 mM EDTA, 
0.5 mM EGTA); and lysis buffer III (10 mM tris-HCl, 2100 mM NaCl, 1 mM EDTA, 0.1% 
sodium deoxycholate, 0.5%N-lauroylsarcosine). Cells were incubated on a rocker at 4C for 
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10 minutes in each lysis buffer after which they were spun down at 1300 g for 5 minutes so 
that the supernatant could be removed. The cells were then sonicated using the Bioruptor in 
seven to fifteen 30-second cycles to generate fragments 100-1000 bp in size. Gel 
electrophoresis in 1% agarose was used to confirm the size of the DNA fragments. The DNA 
was extracted with a standard phenol/chloroform method and ethanol-precipitated. 50ng of 
DNA from paired crosslinked and non-crosslinked cells was analyzed in duplicate by SYBR-
green quantitative PCR (qPCR using primers at roughly 1kb intervals in the 13q22.1 region 
downstream of KLF5 (Supplementary Table 7). The ΔΔCt method31 was used to normalize 
the results to the input DNA from the non-crosslinked cells and then expressed relative to 
the Rhodopsin promoter as a negative control. For each experiment there were two 
replicates for the crosslinked cells and non-crosslinked controls, each performed on two 
occasions. 
 
 
Cross-linked Chromatin immunoprecipitation (ChIP)  
 
About 108 cells were cross-linked using 1% formaldehyde for 10 minutes. Glycine was used 
to stop the cross-linking, cells were then rinsed twice in PBS, and cell scrapers were used to 
detach cells adhered to the Petri dish surface. The cells were then resuspended in lysis 
buffer (1% sodium dodecyl sulfate (SDS), 10 mM EDTA (Ambion), 50mM Tris-HCl (Ambion)) 
and incubated for 10 minutes. The cells were then sonicated using the Bioruptor 
(Diagenode) in 7 to 15 30-second cycles to generate fragments 1000-1500 bp in size. Gel 
electrophoresis in 1% agarose confirmed the size of the DNA fragments. The fragmented 
DNA was then diluted ten times to the immuno-precipitation dilution buffer (1% tritonX-100, 2 
nM EDTA, 20 mM Tris-HCl, 150 mM sodium chloride and each cell line was separated into 
four tubes: input chromatin, no-antibody-control  and one tube for each antibody.  5 ul of 
anti-dimethyl-histone H3 Lys4 (Millipore 07-030) and anti-acetyl-histone H4 (Millipore 06-
866) were added to the antibody tubes and, along with the no-antibody-control, incubated 
overnight at 4C for immunoprecipitation. The input chromatin was kept refrigerated at 4C 
until the reverse cross-linking of day 2. Phenylmethylsulfonyl fluoride and protease inhibitor 
was added to the lysis buffer and IP dilution buffer to deactivate proteases, while sodium 
butyrate was added to these solutions to inhibit histone deacetylases. 5 ul of protein A 
Dynabeads was added to each tube and incubated for 4 hours. A series of washes were 
done using Tris/Sucrose/EDTA (TSE) I (1% tritonX-100, 2 mM EDTA, 20 mM Tris-HCl, 150 
mM NaCl, 0.1 %SDS), TSE II (1% tritonX-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl, 
0.1% SDS), Buffer III (0.25 M lithium chloride, 1 mM EDTA, 10 mM Tris-HCl, 1% tergitol-type 
NP-40, 1% sodium deoxycholate) and tris-EDTA (Tris-EDTA 1X). 300 ul of extraction 
solution (1% SDS 0.1 M sodium bicarbonate) was added and the Dynabeads were removed 
after a 30 minute incubation. Then 0.7 M NaCl was added and reverse cross-linking 
occurred overnight at 65C.  DNA was then purified using the QIAquick PCR purification kit 
(Qiagen) according to the manufacturer's protocol. 1ul of DNA was analyzed in duplicate or 
triplicate by SYBR green qPCR as above and the ΔΔCt method was used to identify areas 
with enrichment. For each experiment there were two replicates for each anti-body along 
with the input and no-antibody control, each performed on two occasions. Primers used are 
listed in Supplementary Table 7.  
 
Chromatin conformation capture (3C) 
 
Experiments were performed as described in Ghoussaini et al.33 Briefly, KLF5-expressing 
Ishikawa endometrial cancer cell lines were crosslinked with 1% formaldehyde for 10 mins, 
quenched with 125mM glycine, washed with PBS and collected by scraping. Cells were 
lysed for 30 min on ice in 10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 0.2% Igepal with protease 
inhibitors and homogenized in a Dounce homogenizer. Nuclei were pelleted and 
resuspended in 1ml 1.2X restriction buffer (NEB 3.1) with 0.3% SDS for 1h at 37°C. 2% 
Triton X-100 was added then 1000U NcoI was added 3 times over 24h at 37°C with shaking. 
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The enzyme was inactivated and digested DNA was diluted 8X before ligation with 4000U of 
T4 DNA ligase overnight at 16°C. Crosslinks were reversed by proteinase K digestion at 
65°C overnight, and then the DNA was purified by phenol–chloroform extraction and ethanol 
precipitation. The final DNA pellet was dissolved in 10 mM Tris (pH 7.5) and purified through 
Amicon Ultra 0.5 ml columns (Millipore). 3C interactions were quantified by SYTO9 qPCR 
(performed on a RotorGene 6000) using primers designed to amplify across ligated NcoI 
restriction fragments with one constant primer within the risk fragment (including rs11841589 
and rs9600103) and a series of test primers within NcoI fragments spanning 76 kb of the 
KLF5 promoter region. BAC clones (RP11-81D9 and RP11-179I20) covering the region 
were digested with NcoI, ligated with T4 ligase and then used determine PCR efficiency. 3C 
analyses were performed on three independent 3C libraries, with each data point in 
duplicate. Data were normalized to the signal from the BAC clone library and from a non-
interacting chromosomal region using the ΔΔCt method with incorporated individual primer 
pair efficiencies. 
 
 
Luciferase reporter assays 
 
For luciferase reporter assays, the regions chr:13 73,810,509-73,813,452 around rs9600103 
and chr13:73,813,268-73,816,290 around rs11841589 were cloned into the pGL3-Promoter 
vector (Promega) to test for regulatory effects in Ishikawa cells. Ishikawa cells were selected 
because they express KLF5, showed evidence of a DHS, FAIRE and H3K4Me2 enrichment 
at rs9600103 and were readily transfectable. Site-directed mutagenesis was used so that 
both the high- and low-risk alleles of rs9600103 and rs11841589 were tested. After 
sequencing to verify the correct insert sequences, cells were transiently co-transfected using 
lipofectamine with the appropriate pGL3-Promoter constructs, and with the Renilla luciferase 
pGL4.75 vector (Promega) as a control for transfection efficiency. After 48 hours, luciferase 
activity was measured (Dual-Glo Luciferase Assay System, Promega), and after subtracting 
background from lipofectamine-only controls, firefly luciferase activity from the putative 
enhancer regions was normalized to the Renilla luciferase values for each sample. Levels of 
firefly luciferase activity were compared with a control plasmid consisting of an empty pGL3 
and also a noncoding 2.2-kb stretch of plasmid sequence (taken from the pENTR1A 
plasmid, Invitrogen) cloned into the pGL3-Promoter vector that we had previously used as a 
length of DNA with no regulatory activity34. Luciferase activity experiments had three or four 
replicates, each performed on three occasions (total of 11 assays). Primers used in these 
experiments are listed in Supplementary Table 5.  
 
ANOVA found significant differences in luciferase levels (P<0.0001, F:11.6) but no 
significant differences between replicates conducted on different days (P=0.91, F:0.09). 
There were no significant differences between the pENTR1A control and the empty pGL3 
vector (P=0.085) and pGL3 no insert is used as the control. We then conducted paired t-
tests for all comparisons using the average of biological repeats, between the pGL3 no 
insert, rs9600103-A, rs9600103-T, rs11841589-G and rs11841589-T fragments 
(Supplementary Table 8).  
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SUPPLEMENTARY NOTE 
 
Detailed Description of the Case and Control Sample Sets 
 
A summary of the studies included in the GWAS and both replication phases is shown in 
Supplementary Table 1, with additional details provided below. Supplementary Figure 1 
provides a flow diagram of the overall study design. All studies were of women of European 
ancestry. All studies have the relevant IRB approval in each country in accordance with the 
principles embodied in the Declaration of Helsinki, and informed consent was obtained from 
all participants. A total of 7,737 cases and 37,144 controls were included in this analysis. 
Cases and controls were matched based on geographical location and case-control 
clustering in principal components analysis (PCA) (Supplementary Figure 1).  
 
EC and control GWAS Sample Sets: 
 
Quality control (QC) was applied to all GWAS sets, following standard QC approaches 
detailed in Spurdle et al1. Also see online methods.  
 
NSECG 
National Study of the Genetics of Endometrial Cancer (NSECG) cases were identified from 
collaborating clinicians throughout the UK from 2008 to 2013, taking care not to recruit from 
centres involved in SEARCH. Inclusion criteria were adenocarcinomas of the uterus 
presenting at 70 years of age or younger. Almost all cases were incident and sampled within 
6 months of diagnosis. Peripheral blood was collected from each participant and DNA 
extracted using standard methods and the participants completed the associated 
questionnaire. Tumour histology was confirmed from routine hospital reports and further 
details of histopathology and other tumor pathology characteristic was abstracted from these 
clinical pathology reports. 925 samples were genotyped using the Ilumina 660W Quads in 
the GWAS scan, 965 samples were genotyped in the phase 1 replication using iCOGS 
arrays, and a further 1195 were genotyped using KASPar and Fluidigm genotyping for the 
second replication phase. There was no overlap in samples used and all cases were of 
European ancestry.  
 
ANECS 
The Australian National Endometrial Cancer Study (ANECS) is an Australian population-
based case-control family study of cancer of the uterine corpus2. Women aged 18-79, newly 
diagnosed with histologically confirmed primary cancer of the endometrium between July 
2005 and December 2007 were identified through major hospitals nationally, and also from 
state-based cancer registries. Excluding women who could not be contacted (mostly due to 
death, illness or failure to contact), case participation rate was 63%. Participants completed 
a detailed questionnaire providing clinical and epidemiological information, including 
ethnicity of all four grandparents. Information on tumor pathology characteristics was 
abstracted in standardized format from clinical pathology reports for all patients. 606 ANECS 
samples all of endometrioid-only histology were used for the original EC GWAS and a 
further 538 were genotyped using iCOGS for the first replication phase.  
 
SEARCH 
The Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH) is an ongoing 
population-based study with cases ascertained through the Eastern Cancer Registration and 
Information Centre (http://www.ecric.org.uk). All women diagnosed with endometrial cancer 
between the ages of 18-69 years (average age of diagnosis 58 years) from August 2001 to 
September 2007 were eligible for inclusion. Approximately 54% of eligible patients have 
enrolled in the study. Women taking part in the study were asked to provide a 20ml blood 
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sample for DNA analysis, and to complete a comprehensive epidemiological questionnaire. 
Controls were also drawn from SEARCH (http://ccge.medschl.cam.ac.uk/search/), but had 
no prior history of cancer at the time of recruitment. They were female, also between the 
ages of 18-69 at the time of recruitment and matched to cases in geographical profile. 
Approximately 35% of eligible controls enrolled in the study. All participants reported 
Caucasian ethnicity. Information on tumor pathology characteristics was provided by the 
Eastern Cancer Registration and Information Centre and was derived from clinical pathology 
reports for all patients. 681 SEARCH samples with endometroid-only histology were used in 
the original GWAS and a further 773 non-overlapping cases were used in the iCOGS 
analysis.  
 
UK1/CORGI 
The UK1 Colorectal Tumour Gene Identification (CoRGI) is a GWAS for colorectal 
neoplasia3. The 894 controls matched with the NSECG cases were spouses or partners 
unaffected by cancer and without a personal family history (to second degree relative level) 
of colorectal neoplasia. Known dominant polyposis syndromes, HNPCC/Lynch syndrome or 
bi-allelic MUTYH mutation carriers were excluded. All cases and controls were of white UK 
ethnic origin. Genotyping was done on the Illumina Hap550 arrays.  
 
Scotland Phase 1 
Scotland Phase1 is a colorectal cancer GWAS4 with 1012 cancer-free population controls 
Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic MUTYH 
mutation carriers were excluded. Control subjects were sampled from the Scottish 
population NHS registers, matched by age (±5 years), gender and area of residence within 
Scotland. A subset of 392 controls from this dataset were matched with the NSECG GWAS 
cases and these were chosen based on case-control clustering on PCA. Genotyping was 
done on the Illumina Hap300 and Hap 240S arrays. 
 
QIMR 
The Queensland Institute of Medical Research (QIMR) control sample is a subsection of 
subjects recruited as part of the Brisbane Adolescent Twin Study5,6. Twins were recruited 
from schools in Brisbane, Australia and surrounding areas of southeast Queensland and 
were examined close to their 12th birthday. Blood was obtained from all twins and most 
parents. Parents were asked the ancestry of all eight great-grandparents of the twins. More 
than 95% of great-grandparents were identified as being of northern European ancestry, 
mainly from Britain and Ireland. This analysis used genotype data from parents and siblings 
only, extracted from an existing Illumina 610K BeadChip genome-wide association scan7 
and recalled using the Illuminus algorithm. After QC, 1846 QIMR controls were available for 
inclusion in the analysis. 
 
HCS 
The Hunter Community Study (HCS) is a population-based cohort study consisting of men 
and women aged 55-85 years of age in Newcastle, New South Wales, Australia8. 
Participants were randomly selected from the NSW State electoral roll (listing on the 
electoral roll is compulsory in Australia) and contacted between December 2004 and 
December 2007. Non-English speaking persons and those living in a residential aged-care 
facility were ineligible for participation in the study. Participants were asked to complete five 
self-report questionnaires as well as attend the HCS data collection centre so clinical 
measures could be obtained. In total, 44.5% of eligible controls agreed to participate in this 
study. Genotype data for this study were extracted from an existing Illumina 610K BeadChip 
genome-wide association study scan and recalled using the Illuminus algorithm. After QC, 
1237 HCS controls were available for inclusion in the analysis.  
 
WTCCC 
 32 
Controls utilized were genotyped as part of the Wellcome Trust Case Control Consortium 
(WTCCC2)
9
.  These controls are drawn from two sources: 2,674 controls from the 1958 Birth 
Cohort (1958BC), a population-based study in the United Kingdom of individuals born in 1 
week in 1958
10
; and 2,501 controls identified through the UK National Blood Service (NBS)
9
. 
1958BC controls were matched with NSECG cases and the NBS controls were matched 
with SEARCH cases.  
 
Phase 1 iCOGS replication Case Sample Sets: 
 
All samples in the first replication phase were genotyped as part of the Collaborative 
Oncological Gene-environment Study (iCOGS) initiative on a custom Ilumina Infinium iSelect 
array. Cases from ANECS and SEARCH and NSECG were recruited as detailed above, and 
are non-overlapping.  
 
BECS 
The Bavarian Endometrial Cancer Cases and Controls Study (BECS) is a single-center 
case-control study, conducted between 2002 and 2008, with the aim of investigating genetic 
and epidemiological risk factors for endometrial cancer. Cases were either incident cases 
referred to the University Hospital Erlangen by surrounding practitioners (66% of the case 
sample set), or prevalent cases that were outpatients in follow-up care approached within 
6.2 (±4.6 SD) years after treatment for primary endometrial cancer in the same hospital 
(34% of the case sample set). Epidemiological information was collected by a structured 
questionnaire completed during an interview and clinical data for the cases was obtained 
from clinical health records. 
 
CAHRES 
Details of the population selection process have been published previously for the Cancer 
Hormone Replacement Epidemiology Study (CAHRES)11. Formerly known as the Singapore 
and Sweden Breast/Endometrial Cancer Study (SASBAC), this population based case-
control study was conducted among Swedish women aged 50-74 years, who were residing 
in Sweden between January 1st 1994 and December 31st 1995. Endometrial cancer cases 
were identified through the nation-wide cancer registries in Sweden. All participants provided 
detailed questionnaire information. For endometrial cancer, histological specimens were 
reviewed and re-classified by the study pathologist. All participants reported Caucasian 
ethnicity.  
 
HJECS 
The Hannover-Jena Endometrial Cancer Study (HJECS), a hospital-based case-control 
study, included 250 German women, aged 31-89 years, who were recruited either at the 
Friedrich Schiller University of Jena or at Hannover Medical School after having been 
diagnosed with histologically confirmed primary incident endometrial carcinoma between 
2004 and 2010. Epidemiological data were obtained from questionnaires, and information on 
tumor stage and histology was obtained from pathology and clinical reports. Over 98% were 
of German descent. Interviews were conducted at either the Friedrich Schiller University of 
Jena or at Hannover Medical School, and peripheral blood was collected for the extraction of 
DNA from white blood cells. 
 
LES 
The Leuven Endometrial Study (LES) is a hospital based case-control study. Eligible cases, 
identified by active surveillance of electronic patient files at the Leuven University Hospital, 
were white women aged 27-80 years diagnosed with endometrial cancer. Clinical data for 
endometrial cancer patients were recorded during interview at the time of diagnosis, and 
from pathology reports. All medical records were reviewed by trained abstractors and 
pathology reports compatible with primary, invasive, epithelial endometrial adenocarcinoma 
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of all stages (I –IV) and all grades were consulted. Participation rates exceeded 95% for 
cases. 
 
MECS  
The Mayo Endometrial Cancer Study (MECS) includes a clinic-based prospective collection 
of primary endometrial cases diagnosed from 2008 to 2011 and seen at Mayo Clinic 
Rochester with primary endometrial cancer diagnosed at age 18 and older. DNA was 
isolated from white blood cells using qiagen isolation kit. DNA concentration was measured 
with picogreen. Clinical data were abstracted from electronic medical records and 
supplemented with a risk factor questionaire. Control data were obtained from Mayo Clinic 
OCAC controls (MAY) and BCAC controls (MCBCS). 
 
MoMaTEC 
Molecular Markers in Treatment of Endometrial Cancer (MoMaTEC) cases were recruited 
from an unselected patient population primarily treated for endometrial carcinoma at 
Haukeland University Hospital, Bergen during 2001-2009. This is the referral hospital for 
Hordaland county; the area is demographically well defined, with about 450,000 inhabitants, 
representing approximately 10% of the Norwegian population and with a similar incidence 
rate and prognosis as the total Norwegian population of endometrial cancers12–14. Clinical 
Information for cases regarding age, FIGO stage, histologic subtype, grade and prognosis 
was extracted from medical records. DNA was extracted from peripheral blood samples. 
 
NECS 
The Newcastle Endometrial Cancer Study (NECS) includes histologically confirmed 
endometrial cancer cases consecutively recruited from 1992 up to 2005 at the Hunter Centre 
for Gynaecological Cancer, John Hunter Hospital, Newcastle, New South Wales, Australia15. 
The final analysis included 194 endometrial cancer patients. Data on reproductive and 
environmental risk factors including ethnicity was collected using self reported 
questionnaires. Information regarding recurrence, stage, grade and histology of endometrial 
cancer was collected from medical records. Patients presenting at this hospital-based site 
were captured by ANECS recruitment from 2005 onwards.  
 
RENDOCAS 
The Registry of Endometrial Cancer in Sweden (RENDOCAS) is a hospital based case-
control study. Patients (n=520) who underwent surgery for endometrial cancer at Karolinska 
University hospital Solna, Sweden between 2008 and 2011 were included in the study. For 
each patient, the following was collected: blood and tumor samples; detailed family history 
and formulation of a pedigree where all suspected cancer cases were verified in medical 
records/pathology report if possible; questionnaire covering relevant environmental factors 
underlying endometrial cancer.  
 
iCOGS Control Sample Sets: 
 
As indicated in Supplementary Table 1, iCOGS endometrial cancer case sample sets were 
matched with controls from the same countries and also clustered with cases in PCA 
(Supplementary Figure 2). Controls were genotyped using the same iCOGS array and data 
were largely drawn from healthy controls participating in the Breast Cancer Association 
Consortium (BCAC)16 part of the iCOGS initiative. Additional controls were from the Mayo 
Clinic via the Ovarian Cancer Association Consortium (OCAC)17,  and Norwegian female 
controls recruited in Bergen for use in the MoMaTEC case-control genotyping studies. 
 
Endometrioid and non-endometrioid histology analysis 
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Cases were defined as having endometrioid subtype based on pathology report of 
endometrioid histology only. Non-endometrioid subtypes included carcinosarcoma, clear 
cell, serous, mucinous, and tumours of mixed histology (any combination). 6,635 (86%) of 
the 7,737 EC cases displayed endometrioid-only histology and association testing and meta-
analysis was also conducted using endometrioid-only histology cases. The results of this 
analysis for the novel risk loci are shown in Table 1. Endometrioid-only phase 1 meta-
analysis (n=5,590) found only novel risk loci that were identified in the all histologies analysis 
(Table 1, Supplementary Table 2). Analysis of 952 EC cases that displayed non-
endometrioid histology found no SNPs near genome-wide significance and this is expected 
given the limited statistical power.  
 
Ishikawa and ECC-1 cells 
 
Results from Ishikawa and ECC-1 cells are listed separately in publicly available ENCODE18 
tier 3 data but STR-profiling has shown that these two cell lines are very similar19. Based on 
the results presented by Korch et al., the International Cell Line Authentication Committee 
(ICLAC) recommended in the 2013 Database of Cross-Contaminated or Misidentified Cell 
Lines that ECC-1 be re-identified as Ishikawa cells. Our in vitro functional analysis for the 
13q22 locus made use of our supply of Ishikawa cells for FAIRE and ChIP experiments and 
ECC-1 cells for luciferase reporter assays. Both cell lines displayed identical genotypes for 
rs9600103 and rs11841589, similar KLF5 expression levels, and 20x sequencing using the 
Ion AmpliSeq™ Comprehensive Cancer Panel confirmed that variants in Ishikawa and ECC-
1 are 90% concordant (based on 3,004 exonic SNVs in 409 cancer-related genes). In line 
with these findings and ICLAC recommendations, we have presented functional work on 
these cells as Ishikawa cells.  
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Supplementary Figure 1: EC meta-analysis flow diagram.  
This schematic figure illustrates the EC meta-analysis study design. The new NSECG 
GWAS was meta-analysed with a re-analysis of the original EC GWAS (ANECS and 
SEARCH) and phase 1 iCOGS replication (eight groups). This meta-analysis of 6,542 cases 
and 36,393 controls yielded 14 regions with SNPs P<10-5, of which five regions had SNPs 
P<10-7. These five SNPs were brought forward to the phase 2 NSECG replication and were 
confirmed as novel genome-wide significant risk loci (P<5×10−8) in the overall meta-analysis 
of 7,737 cases and 37,144 controls.  
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Supplementary Figure 2: Principal Components Analysis (PCA) of three GWAS and 
eight iCOGS studies.  
Plots of the first two principal components (PCs) in each study. EC cases are represented by 
blue dots, whereas controls are in black. Samples were excluded if they clustered away from 
the centroid in the first four PCs and these are plots of the samples used in the analysis.  
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Supplementary Figure 3: Quantile-quantile plots of the ranked trend test statistics for 
three GWAS and eight iCOGS groups.  
The –log10 transformed observed P-values (y-axis) were plotted against the expected P-
values under the null hypothesis (x-axis). The red line denotes the expectation under no 
deviation from the null hypothesis. The QQ-plots show little evidence of genomic inflation 
and the λGC for each study are: NSECG GWAS 1.020, ANECS GWAS 1.021, SEARCH 
GWAS 1.002, ANECS iCOGS 1.036, SEARCH iCOGS 1.016, NESCG iCOGS 1.038, MECS 
iCOGS 1.007, LES iCOGS 1.034, BECS iCOGS 1.030, MoMaTEC iCOGS 1.034, CAHRES 
RENDOCAS iCOGS 1.037. For the three GWAS, all genotyped SNPs passing QC are 
displayed. For iCOGS, 105,000 SNPs after LD-pruning (r2<0.2) and >500kb from the 1,483 
EC prioritized SNPs on the iCOGS are displayed.  
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Supplementary Figure 4: Regional association plots for the five novel loci associated 
with endometrial cancer. 
The -log10 P values from the meta-analysis and regional imputation for NSECG, ANECS, 
SEARCH, and eight iCOGS groups are shown for SNPs at: a) 13q22.1, b) 6q22, c) & d) 
8q24, e) 15q15 and f) 14q32.33. The SNP with the lowest P value at each locus is labelled 
and marked as a purple diamond, and the dot color represents the LD with the top SNP. The 
blue line shows recombination rates in cM/Mb. Compared with Figure 2, more SNPs are 
displayed in these plots. SNPs with info scores of more than 0.6 in iCOGS and more than 
0.9 in NSECG, ANECS, and SEARCH are included.  
 
 
 40 
  
  
  
 41 
Supplementary Figure 5: Genetic landscape of novel endometrial cancer associated regions.  
Plots for novel risk loci at a) 13q22.1, b) 6q22.31, c) 8q24.21, d) 15q15 and e) 14q32. SNPs in strong LD (r2 > 0.7) with the lead EC-risk SNP 
have been plotted for each region and the lead SNP denoted in green. The second, independently associated SNP found at 8q24.21 after 
conditioning on the lead SNP is denoted in red (c). Previously reported cancer risk SNPs identified by GWAS at 8q24 are shown in blue (c), 
none of which are in LD (r2≤0.02) with EC risk SNPs. Likely enhancers identified by Hnisz et al.20 and PresTIGE21 that overlap EC-risk 
associated SNPs are depicted as colored bars, where the color of the likely enhancer matches the schematic of its predicted target gene, as 
determined by correlations with gene expression. As described in Online Methods Hnisz et al. predicted enhancer-gene interactions by 
identifying 'super-enhancers' (regions containing neighboring H3K27Ac modifications) from 86 cell and tissue types and then the expressed 
transcript with transcription start site closest to the centre of the super-enhancer was assigned as the target gene. PresTIGE pairs cell-type 
specific H3K4Me1 and gene expression data from 13 cell types to identify likely enhancer-gene interactions. Additional tracks include: Histone 
modifications associated with promoters (H3K4Me3) and enhancers (H3K4Me1 and H3K27Ac) from seven ENCODE Project cell types; DNaseI 
hypersensitivity sites (DHS) and transcription factor (TF) binding identified in 125 and 91 ENCODE Project cell types, respectively; DHS 
identified in Ishikawa endometrial cancer cells using DMSO vehicle and under estrogen (E2) stimulation are shown; transcription factor binding 
regions in Ishikawa cells that encompass EC-risk SNP loci are also displayed. For all risk loci, EC-risk associated SNPs co-locate with at least 
one enhancer predicted by cell-type specific analysis, implicating the following genes/transcripts as worthy of investigation: a) KLF5; b) HEY2, 
NCOA7; c) MYC, MIR1204, MIR1205, MIR1207, MIR1208; d) BMF, GPR176, SRP14, LOC100131089; e) AKT, ADSSL1, INF2, ZBTB42, 
SIVA1. For four loci (a, c, d and e), likely enhancers overlap with at least one region displaying evidence of regulatory activity (DHS and/or TF 
binding) in the single endometrial cancer cell line (Ishikawa) assayed by ENCODE.   
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Supplementary Figure 6: Hi-C chromatin capture of 13q22 locus in Hela S3 cells. a) 
5Kb KR normalized contact matrix in Hi-C experiment for HeLa S3 cells was used to 
represent the interaction pattern between KLF5 and risk locus rs11841589/rs960010322. A 
loop was anchored at the KLF5 promoter and the risk locus (see b) for the small 
topologically associated domain and the red arrow for loop anchor), which indicated distal 
cis-regulatory element with in the risk locus. The interaction between the 
rs11841589/rs9600103 risk locus with the KLF5 promoter was the strongest interaction 
observed out of the 262 protein-coding genes on chromosome 13 (P=0.004). The color 
scheme in the contact matrix is KR normalized score with the black indicating a strong 
interaction.  
 
 
 
 
  
 47 
Supplementary Figure 7: Quantification of KLF5 expression in EC cell lines 
Expression of KLF5 in 11 EC cell lines as described in Online methods using qRT-PCR, 
expression levels on the x-axis are relative to KLF5 expression in Ishikawa cells using the 
ddCT method.  
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